These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
183 related articles for article (PubMed ID: 24603974)
1. Extensive bilateral lower extremity deep venous thrombosis in a patient on dimethyl fumarate. Ratchford EV; Baldanza JT; Pardo CA J Neurol; 2014 Apr; 261(4):831-2. PubMed ID: 24603974 [No Abstract] [Full Text] [Related]
2. Lower extremity deep venous thrombosis in a multiple sclerosis patient on dimethyl fumarate. Mirmosayyeb O; Fayyazi E; Shaygannejad V; Esmaeil N Mult Scler Relat Disord; 2018 Oct; 25():196. PubMed ID: 30099205 [No Abstract] [Full Text] [Related]
3. Lorcaserin, dimethyl fumarate, and bedaquiline fumarate. Hussar DA; Polyak G J Am Pharm Assoc (2003); 2013; 53(3):328-30, 332, 334. PubMed ID: 23699683 [No Abstract] [Full Text] [Related]
4. Dimethyl fumarate for treatment of multiple sclerosis: mechanism of action, effectiveness, and side effects. Linker RA; Gold R Curr Neurol Neurosci Rep; 2013 Nov; 13(11):394. PubMed ID: 24061646 [TBL] [Abstract][Full Text] [Related]
5. PML in a patient with lymphocytopenia treated with dimethyl fumarate. Rosenkranz T; Novas M; Terborg C N Engl J Med; 2015 Apr; 372(15):1476-8. PubMed ID: 25853765 [No Abstract] [Full Text] [Related]
6. Multiple sclerosis in 2012: Novel therapeutic options and drug targets in MS. Methner A; Zipp F Nat Rev Neurol; 2013 Feb; 9(2):72-3. PubMed ID: 23338282 [TBL] [Abstract][Full Text] [Related]
7. Dimethyl fumarate (Tecfidera): a new oral agent for multiple sclerosis. Venci JV; Gandhi MA Ann Pharmacother; 2013 Dec; 47(12):1697-702. PubMed ID: 24259625 [TBL] [Abstract][Full Text] [Related]
8. Dimethyl fumarate (Tecfidera) for multiple sclerosis. Med Lett Drugs Ther; 2013 Jun; 55(1418):45-7. PubMed ID: 24662841 [No Abstract] [Full Text] [Related]
9. Eosinophilic gastroenteritis in a woman with multiple sclerosis on dimethyl fumarate. Purchiaroni F; Salvetti M; Buscarinu MC; Annibale B Neurology; 2016 Aug; 87(9):952-3. PubMed ID: 27466473 [No Abstract] [Full Text] [Related]
10. Multiple sclerosis: oral BG12 for treatment of relapsing-remitting MS. Limmroth V Nat Rev Neurol; 2013 Jan; 9(1):8-10. PubMed ID: 23147843 [No Abstract] [Full Text] [Related]
11. Improving the Gastrointestinal Tolerability of Fumaric Acid Esters: Early Findings on Gastrointestinal Events with Diroximel Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis from the Phase 3, Open-Label EVOLVE-MS-1 Study. Palte MJ; Wehr A; Tawa M; Perkin K; Leigh-Pemberton R; Hanna J; Miller C; Penner N Adv Ther; 2019 Nov; 36(11):3154-3165. PubMed ID: 31538304 [TBL] [Abstract][Full Text] [Related]
13. Response to comment on "Dimethyl fumarate (tecfidera): a new oral agent for multiple sclerosis". Venci J; Gandhi MA Ann Pharmacother; 2014 Nov; 48(11):1537. PubMed ID: 25301830 [No Abstract] [Full Text] [Related]
14. Second oral MS drug wins FDA nod. Sheridan C Nat Biotechnol; 2013 May; 31(5):373. PubMed ID: 23657376 [No Abstract] [Full Text] [Related]
15. The New England Journal of Medicine publishes pivotal data demonstrating efficacy and safety of oral BG-12 (dimethyl fumarate) in multiple sclerosis. Fox R Can J Neurosci Nurs; 2012; 34(3):7-11. PubMed ID: 23362583 [No Abstract] [Full Text] [Related]